(Q54470532)

30 May 2018

title

Validated gene targets associated with curatively treated advanced serous ovarian carcinoma. (English)

1 reference

30 May 2018

8

Dennis S Chi

1 reference

30 May 2018

Richard R Barakat

7

object named as

Richard R Barakat

1 reference

30 May 2018

author name string

Joyce N Barlin

1

1 reference

30 May 2018

Petar Jelinic

2

1 reference

30 May 2018

Narciso Olvera

3

1 reference

30 May 2018

Faina Bogomolniy

4

1 reference

30 May 2018

Maria Bisogna

5

1 reference

30 May 2018

Fanny Dao

6

1 reference

30 May 2018

Douglas A Levine

9

1 reference

30 May 2018

language of work or name

English

0 references

publication date

17 November 2012

1 reference

30 May 2018

published in

Gynecologic Oncology

1 reference

30 May 2018

volume

128

1 reference

30 May 2018

issue

3

1 reference

30 May 2018

page(s)

512-517

1 reference

30 May 2018

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Microarray analysis of early stage serous ovarian cancers shows profiles predictive of favorable outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Integrated genomic analyses of ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Direct multiplexed measurement of gene expression with color-coded probe pairs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

mRNA transcript quantification in archival samples using multiplexed, color-coded probes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Clinical characteristics of patients with prolonged disease-free survival after primary treatment in advanced ovarian cancer: a brief report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Gene expression profiling predicts clinical outcome of breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy

7 January 2021

2 references

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

7 January 2021

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

inferred from DOI database lookup

7 January 2021

based on heuristic

Gene expression signature with independent prognostic significance in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

CYP4B1: an enigmatic P450 at the interface between xenobiotic and endobiotic metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Choline metabolism in malignant transformation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Selective inhibition of choline kinase simultaneously attenuates MAPK and PI3K/AKT signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Alterations of choline phospholipid metabolism in ovarian tumor progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

Activation of phosphatidylcholine cycle enzymes in human epithelial ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

High-throughput screening identifies CHMP4A associated with hypoxia-inducible factor 1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.11.018

10.1016/J.YGYNO.2012.11.018

7 January 2021

Identifiers

DOI

1 reference

30 May 2018

1 reference

30 May 2018